Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pavel Belomestnov"'
Autor:
Pavel Belomestnov, Mohamed Sebai, Steven P. Weinstein, Martin L. Throne, Alan Kivitz, Scott Mellis, Hal M. Hoffman, N.J. Amar, Neil Stahl, George D. Yancopoulos, Arthur Kavanaugh
Publikováno v:
Arthritis & Rheumatism. 58:2443-2452
Objective To assess the efficacy and safety of rilonacept (Interleukin-1 [IL-1] Trap), a long-acting and potent inhibitor of IL-1, in patients with cryopyrin-associated periodic syndromes (CAPS), including familial cold autoinflammatory syndrome (FCA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5cc48b00a02971ad490ffa4a52bccedd
https://doi.org/10.1002/art.23687
https://doi.org/10.1002/art.23687
Publikováno v:
Current Medical Research and Opinion. 24:2531-2543
Development of an instrument for characterization of symptom patterns and severity in patients with cryopyrin-associated periodic syndromes (CAPS).Two generations of daily health assessment forms (DHAFs) were evaluated in this study. The first-genera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::35e83044e70f265b6f17f978be64feaa
https://doi.org/10.1185/03007990802297495
https://doi.org/10.1185/03007990802297495
Publikováno v:
Journal of clinical pharmacology. 50(7)
The safety and pharmacokinetics of a single dose of the IL-1 inhibitor, rilonacept (IL-1 Trap; 160 mg, subcutaneously), was studied in a group of 6 patients with well-controlled end-stage renal disease (ESRD) who were observed for a period of 42 days
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::47cf5ac7b12a8a3dd37aea0964389eea
https://pubmed.ncbi.nlm.nih.gov/20035038
https://pubmed.ncbi.nlm.nih.gov/20035038
Autor:
Lisa A. Beck, Brian N. Swanson, Gianluca Pirozzi, Lin Wang, Sally E. Wenzel, Thomas Diciccio, Pavel Belomestnov, Neil M.H. Graham, Haobo Ren, Jeffrey Ming, Yongtao Li, Jennifer D. Hamilton
Publikováno v:
The World Allergy Organization Journal
Dupilumab (DPL) is a fully human IL-4Rα monoclonal antibody that potently inhibits both IL-4 and IL-13 signaling, drivers of T-helper 2 (Th2) mediated inflammation. In early clinical trials, DPL has recently been evaluated in proof-of-concept studie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69c1df5409fac8dcbf7f6d92ed0f485a
http://europepmc.org/articles/PMC4082126
http://europepmc.org/articles/PMC4082126
Autor:
Hal M. Hoffman, S.P. Weinstein, R.C. Cartwright, Scott Mellis, Pavel Belomestnov, N.J. Amar, A.J. Kivitz
Publikováno v:
Journal of Allergy and Clinical Immunology. 121:S175-S175
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ea99af5267ab4cd33f2ff838f8c884a6
https://doi.org/10.1016/j.jaci.2007.12.643
https://doi.org/10.1016/j.jaci.2007.12.643
Autor:
I.M. Grimes, S.P. Weinstein, D.R. Stein, Hal M. Hoffman, Scott Mellis, E.P. Boling, Pavel Belomestnov, N.J. Amar, C. Vicary, M.L. Throne
Publikováno v:
Journal of Allergy and Clinical Immunology. 119:524
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cc7dbe598e8ccdae2da829776efbfb13
https://doi.org/10.1016/j.jaci.2006.12.631
https://doi.org/10.1016/j.jaci.2006.12.631
Publikováno v:
Current Medical Research & Opinion; Sep2008, Vol. 24 Issue 9, p2531-2543, 13p